Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

181.69 +1.15 (+0.64%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Natera Named to Fast Company’s Next Big Things in Tech List
From Natera, Inc.
Via Business Wire
Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings
From Natera, Inc.
Via Business Wire
Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
From Natera, Inc.
Via Business Wire
Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT
From Natera, Inc.
Via Business Wire
Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer
From Natera, Inc.
Via Business Wire
Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows
From Natera, Inc.
Via Business Wire
Natera Provides Update on Patent Litigation with NeoGenomics
From Natera, Inc.
Via Business Wire
Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer
From Natera, Inc.
Via Business Wire
Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer
From Natera, Inc.
Via Business Wire
Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine
From Natera, Inc.
Via Business Wire
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
From Natera, Inc.
Via Business Wire
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
From Natera, Inc.
Via Business Wire
Natera Reports Second Quarter 2025 Financial Results
From Natera, Inc.
Via Business Wire
Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions
From Natera, Inc.
Via Business Wire
Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations
From Natera, Inc.
Via Business Wire
Natera to Report Its Second Quarter Results on August 7, 2025
From Natera, Inc.
Via Business Wire
Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer
From Natera, Inc.
Via Business Wire
PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT
From Natera, Inc.
Via Business Wire
Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer
From Natera, Inc.
Via Business Wire
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
From Natera, Inc.
Via Business Wire
Natera Announces Medicare Coverage for Signatera™ Genome
From Natera, Inc.
Via Business Wire
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
From Natera, Inc.
Via Business Wire
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
From Natera, Inc.
Via Business Wire
Natera Reports First Quarter 2025 Financial Results
From Natera, Inc.
Via Business Wire
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
From Natera, Inc.
Via Business Wire
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
From Natera, Inc.
Via Business Wire
Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera
From Natera, Inc.
Via Business Wire
Natera to Report its First Quarter Results on May 8, 2025
From Natera, Inc.
Via Business Wire
Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction
From Natera, Inc.
Via Business Wire
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback